Novartis Patent Case in India

It's the standard treatment of IP arguments and trade offs:

The treatment of thousands of AIDS patients will be in jeopardy if Swiss drug maker Novartis succeeds in changing India's patent law, Medecins Sans Frontieres (MSF) has warned.

Here's a summary time line of Patent Law in India.

Another article puts it this way:

Profit over life

In 2000, antiretroviral (ARV) treatment cost was estimated at $10,000 per patient annually. But the availability of generic drugs produced mainly in India, allowed costs to plummet to about $70 per patient per year, Mwangi adds.

They do briefly mention:

Novartis argues that the principle of intellectual property protection must be safeguarded if innovation is to flourish.